Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Roivant presented its financial results for the first quarter ending June 30, 2025, reflecting a period described as relatively quiet but setting the stage for significant events in the upcoming months.</li><li>The company is primarily focused on its diverse pipeline of biopharmaceutical endeavors, comprising significant R&D progressions and ongoing litigation matters.</li><li>This analysis will cover these key areas of their operational focus and financial strategy.</li></ul>

Roivant presented its financial results for the first quarter ending June 30, 2025, reflecting a period described as relatively quiet but setting the stage for significant events in the upcoming months.The company is primarily focused on its diverse pipeline of biopharmaceutical endeavors, comprising significant R&D progressions and ongoing litigation matters.This analysis will cover these key areas of their operational focus and financial strategy.

Roivant Sciences: An Insight Into The Progress in Brepocitinib Trials & Key Growth Levers!

<ul><li>Roivant Sciences, in its most recent fiscal year-end earnings, reported a period of significant activity and progress across several fronts.</li><li>The company emphasized advancements in its late-stage pipeline, particularly in its anti-FcRn franchise and developments in brepocitinib.</li><li>The fiscal year was marked by the generation of critical data from studies involving batoclimab in Myasthenia Gravis and CIDP, as well as anticipation for pivotal data from brepocitinib in dermatomyositis, which could lead to novel treatments with significant lead-time advantages.</li></ul>

Roivant Sciences, in its most recent fiscal year-end earnings, reported a period of significant activity and progress across several fronts.The company emphasized advancements in its late-stage pipeline, particularly in its anti-FcRn franchise and developments in brepocitinib.The fiscal year was marked by the generation of critical data from studies involving batoclimab in Myasthenia Gravis and CIDP, as well as anticipation for pivotal data from brepocitinib in dermatomyositis, which could lead to novel treatments with significant lead-time advantages.

How Roivant Sciences Could Score Big Wins Through High-Stakes IP Battles with Pharma Giants!

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>The HHS rescheduled the CDC’s postponed February ACIP (vaccine experts panel) meeting for mid-April, with a revised agenda to include the ongoing measles outbreak.</li><li>Flu vaccine guidelines for fall strains are not on the schedule, as the <span style="font-size: var(--content-font-size);">FDA issued recommendations without the usual ACIP guidance. </span></li><li><span style="font-size: var(--content-font-size);">The </span>CDC’s Division of HIV Prevention is under review, which could disrupt a major funding source of HIV prophylaxis (PrEP) drugs (GILD, GSK). </li></ul>

The HHS rescheduled the CDC’s postponed February ACIP (vaccine experts panel) meeting for mid-April, with a revised agenda to include the ongoing measles outbreak.Flu vaccine guidelines for fall strains are not on the schedule, as the FDA issued recommendations without the usual ACIP guidance. The CDC’s Division of HIV Prevention is under review, which could disrupt a major funding source of HIV prophylaxis (PrEP) drugs (GILD, GSK). 

Biopharma Week in Review - March 24, 2025

<ul><li>Roivant, a biopharmaceutical firm, reported its financial results and progress on clinical programs for the first quarter of the fiscal year 2024 during an earnings call led by CEO Matthew Gline.</li><li>This quarter, Roivant emphasized its ongoing efforts in expanding and executing its clinical pipeline, highlighting several key updates and future expectations.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Roivant, a biopharmaceutical firm, reported its financial results and progress on clinical programs for the first quarter of the fiscal year 2024 during an earnings call led by CEO Matthew Gline.This quarter, Roivant emphasized its ongoing efforts in expanding and executing its clinical pipeline, highlighting several key updates and future expectations.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Roivant Sciences Ltd.: Expansion of VTAMA Applications & Clinical Pipeline Developments Driving Our Bullishness! - Major Drivers

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>Our long-term outlook remains neutral on the S&amp;P 500 (SPX) as of our 8/6/24 Compass, after being bullish since early-November 2023.</li>
<li>Since late-July discussed expectations for a 1-to 4-month pullback/consolidation on SPX and QQQ; now it's likely to last closer to four months, and potentially 4- to 6-months from 7/17/24.</li>
<li>At that point the market will decide which way this consolidation resolves. Throughout this pullback we have said that this consolidation could end up being a significant topping pattern.</li>
</ul>


Our long-term outlook remains neutral on the S&amp;P 500 (SPX) as of our 8/6/24 Compass, after being bullish since early-November 2023.
Since late-July discussed expectations for a 1-to 4-month pullback/consolidation on SPX and QQQ; now it's likely to last closer to four months, and potentially 4- to 6-months from 7/17/24.
At that point the market will decide which way this consolidation resolves. Throughout this pullback we have said that this consolidation could end up being a significant topping pattern.


Upgrading Staples, Real Estate, and Health Care to Overweight; List of Concerns Continues to Grow

United States

Roivant Sciences Ltd. operates as a healthcare company. The Company offers investigational drugs in development for therapeutic areas such as dermatology, immunology, and respiratory diseases, as well as provides healthcare technologies which help healthcare institutions share and aggregate data. Roivant Sciences provides services worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Roivant Sciences Ltd (ROIV US)

Roivant Sciences: An Insight Into The Progress in Brepocitinib Trials & Key Growth Levers!

Roivant presented its financial results for the first quarter ending June 30, 2025, reflecting a period described as relatively quiet but setting...

Baptista Research

How Roivant Sciences Could Score Big Wins Through High-Stakes IP Battles with Pharma Giants!

Roivant Sciences, in its most recent fiscal year-end earnings, reported a period of significant activity and progress across several fronts. The...

Baptista Research

Biopharma Week in Review - March 24, 2025

The HHS rescheduled the CDC’s postponed February ACIP (vaccine experts panel) meeting for mid-April, with a revised agenda to include the ongoing...

Water Tower Research

Roivant Sciences Ltd.: Expansion of VTAMA Applications & Clinical Pipeline Developments Driving Our Bullishness! - Major Drivers

Roivant, a biopharmaceutical firm, reported its financial results and progress on clinical programs for the first quarter of the fiscal year 2024...

Baptista Research

Upgrading Staples, Real Estate, and Health Care to Overweight; List of Concerns Continues to Grow

Upgrading Staples $XLP, Real Estate $XLRE, Health Care $XLV to Overweight; List of Concerns Continues to Grow; Dow $DJI, Equal-Weight S&P 500 $RSP,...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)